ActiTrexx GmbH | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ActiTrexx GmbH

BRIEF

published on 10/20/2025 at 10:05, 1 month 15 days ago

ActiTrexx Completes Final Patient Treatment in GvHD Therapy Study

Clinical Study Graft-versus-Host Disease Actileucel Immune Therapy Regulatory T Cells
PRESS RELEASE

published on 10/20/2025 at 10:00, 1 month 15 days ago

ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease
ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease. Phase Ib/II study evaluates Actileucel for GvHD prevention

ActiTrexx Graft-versus-Host Disease Regulatory T Cell Therapy Actileucel Phase Ib/II Study
BRIEF

published on 03/19/2024 at 10:05, 1 year 8 months ago

ActiTrexx Initiates Treatment in Graft-versus-Host Disease Study with Novel T Cell Therapy

Clinical Study ActiTrexx Graft-versus-Host Disease Regulatory T Cell Therapy Actileucel
PRESS RELEASE

published on 03/19/2024 at 10:00, 1 year 8 months ago

ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease
ActiTrexx GmbH treats first patient with novel regulatory T cell therapy for Graft-versus-Host Disease. Phase Ib/II study evaluates safety and feasibility of Actileucel treatment

Graft-versus-Host Disease Regulatory T Cell Therapy Actileucel ActiTrexx GmbH Phase Ib/II Study

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 33 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 38 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 8 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 3 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 8 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 37 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 17 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 42 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 53 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 57 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 8 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 23 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 23 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 7 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE